Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and
characterized in 1999. It is required for the generation of all monomeric forms of amyloid-β …

Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of
evidence from laboratories and clinics worldwide support the concept that an imbalance …

Alzheimer disease (AD) is the most common cause of dementia in older individuals (> 65
years) and has a long presymptomatic phase. Preventive therapies for AD are not yet …

Amyloid precursor protein (APP) gives rise to the amyloid-β peptide and thus has a key role
in the pathogenesis of Alzheimer disease. By contrast, the physiological functions of APP …

The intramembrane protease γ-secretase is a hetero-tetrameric protein complex with
presenilin as the catalytic subunit and cleaves its membrane protein substrates within their …

Proteolytic removal of membrane protein ectodomains (ectodomain shedding) is a post‐
translational modification that controls levels and function of hundreds of membrane …

Alzheimer's disease (AD) is considered to be the most common cause of dementia and is an
incurable, progressive neurodegenerative disorder. Current treatment of the disease …

The β secretase, widely known as β-site amyloid precursor protein cleaving enzyme 1
(BACE1), initiates the production of the toxic amyloid β (Aβ) that plays a crucial early part in …

Alzheimer disease (AD) is characterized by the accumulation of amyloid plaques, which are
predominantly composed of amyloid-β peptide. Two principal physiological pathways either …